Who Do We Trust With Our Health?
The debate over American healthcare isn't about whether gatekeepers will exist. It's about who those gatekeepers are legally accountable to.
One of the most persistent arguments in American political discourse begins with a line I have heard hundreds of times: I don't want the government standing between me and my doctor.
It is a deeply held sentiment, rooted in a genuine desire for autonomy, and it deserves to be taken seriously rather than dismissed. But whether you hold that position or not, it carries an immediate, pragmatic follow-up question that the argument almost never asks.
If the government isn't managing the gate, who is managing it right now?
For the vast majority of Americans, the answer isn't "me." The answer is a private insurance corporation — an entity whose board of directors owes a fiduciary duty to its shareholders under corporate law, a legal obligation that shapes the incentive architecture the entire organization operates within. That doesn't make insurance executives villains. It simply means their system is running exactly as designed based on its core incentives. And those incentives deserve an honest audit.
The Gate Is Already There
There is no modern healthcare model on Earth that operates without gatekeeping of some kind. Every system has an administrative layer determining which procedures require prior authorization, which medications make the approved formulary, which providers are accessible without financial penalty, and what percentage of a catastrophic bill lands in your lap. Those friction points do not vanish when the state steps back. The authority doesn't disappear — it shifts from a civic bureaucracy to a commercial one.
The actual debate has never been whether someone holds authority over your care. Someone always will. The real debate is about governance and accountability — who that authority answers to, what legal mandate it operates under, and what mechanisms exist to challenge its decisions. A public health authority answers to democratic elections and public oversight, however imperfect those mechanisms are. A private insurer answers to its shareholders, and the policyholder's recourse is limited to switching providers if their employer's plan allows it, or filing an appeal through a process the insurer itself administers.
Before making the case for one architecture over the other, the outcome data is worth looking at plainly. The United States spent an estimated $14,885 per person on healthcare in 2024 — the highest per capita healthcare costs among comparable wealthy nations by a significant margin, with Switzerland second at $9,963 and the average for wealthy OECD nations excluding the US at $7,371. Despite spending roughly twice what peer nations spend per person, U.S. life expectancy peaked at 79 years in 2024, two years below the OECD average and third-lowest among all OECD countries. The US ranks last in overall performance among peer countries across access, equity, outcomes, and administrative efficiency according to the Commonwealth Fund's 2024 analysis. The gap between what the system costs and what it delivers is the defining feature of the American healthcare architecture, and it shows up in nearly every major category measured.
Healthcare is also a sector that fails to behave like a standard consumer market under pressure. A person shopping for a television has genuine consumer leverage — they can compare options, wait for a better price, or walk away. A stroke, a cardiac arrest, or a pediatric cancer diagnosis offers none of that. You cannot bargain-shop from the back of an ambulance. You cannot wait for a better deal on insulin when your prescription runs out. When a consumer is operating under extreme distress, with zero price transparency and non-negotiable demand, the pricing discipline that markets theoretically impose breaks down entirely — and the entity on the other side of the transaction holds all of the leverage.
The Honest Case Against Single-Payer
Fairness requires taking the counter-argument seriously, because the people who make it are not simply defending corporate profits, and the problems they identify are real.
Every functioning single-payer or universal system in the world makes rationing decisions that a private market, at least in theory, distributes differently. Wait times for elective procedures in Canada and the United Kingdom are genuinely longer than in the United States for patients with good private coverage. Cost-containment in publicly financed systems requires someone to decide which treatments are worth funding at which price points — a form of gatekeeping that is political and bureaucratic rather than financial, but is still gatekeeping. Centralized systems can be slow to adopt innovations that haven't yet cleared the cost-effectiveness threshold required for public formulary inclusion, which creates a legitimate argument that market-based systems accelerate certain kinds of medical progress.
The transition costs are also not trivial. A system that currently employs hundreds of thousands of people in insurance administration, billing, and claims processing would require a managed restructuring that no serious single-payer advocate claims is simple. The financing question — how a Medicare for All system would be funded, who would bear the tax burden, and whether the total system cost to individuals and employers would actually decrease even if the federal outlay increased — is a genuine policy debate with honest disagreement among economists, not a settled question that one side is simply refusing to acknowledge.
What the outcome data suggests, and what the standard counter-argument tends not to engage, is that the United States is already spending more than enough money per capita to fund universal coverage comparable to peer nations — the question is where that money currently goes and who captures it. Administrative costs in the US healthcare system run significantly higher than in single-payer systems, in large part because the complexity of billing across thousands of different payers with different formularies, authorization requirements, and reimbursement rates requires an administrative apparatus that countries with unified systems simply don't need. The inefficiency is not incidental to the current architecture. It is structural.
The core diagnostic question isn't whether public or private infrastructure handles healthcare — modern systems in virtually every country touch both. The question is whether the architecture we have built produces acceptable results for the resources it consumes. By the metrics that matter — cost per person, life expectancy, access equity, administrative efficiency — the American system does not. That is not a political claim. It is a measurement.
Power over your healthcare choices will exist regardless of which architecture manages it. The question worth asking is whose hands it belongs in, what legal mandate those hands operate under, and whether the people affected by those decisions have any meaningful way to hold them accountable when they get it wrong.
Those are not abstract philosophical questions. They are engineering questions. And the outcome data suggests the current build has significant problems that a mission statement alone cannot fix.